NKTR
Nektar Therapeutics
$71.35
+$0.62 (+0.88%)Jul 27, 2026
Key metrics
The numbers that frame NKTR today
- Market cap
- $2.41B
- P/E (TTM)
- -15.2
- EV / FCF
- -11.5
- Gross margin
- 100%
- EV / Sales
- 42.1
- ROIC
- -36.6%
- Div yield
- 0%
- Debt / equity
- 0.1
- 52wk Low
- $21.02
- 52wk High
- $109.00
Growth
Revenue and earnings trend for NKTR
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about NKTR
Is Nektar Therapeutics a good buy?
Hold. Nektar Therapeutics has excellent momentum, but poor quality makes the setup mixed. Growth looks excellent, which supports the long-term business case. We think Nektar Therapeutics is selling at a very high price.
What is the market capitalization of NKTR?
Nektar Therapeutics's market capitalization is $2.41B.
What is the P/E ratio for NKTR stock?
Nektar Therapeutics's current P/E ratio is -15.2.
What is the 52-week high for NKTR stock?
The 52-week high for Nektar Therapeutics is $109.00. The current close of $71.35 is 34.5% below that high.
What is the 52-week low for NKTR stock?
The 52-week low for Nektar Therapeutics is $21.02. The current close of $71.35 is 239.4% above that low.
Does NKTR stock pay dividends?
Nektar Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for NKTR?
Nektar Therapeutics's Debt / Equity ratio is 0.14.